vadimezan has been researched along with Disease Models, Animal in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Cornwall, SMJ; Graham, PT; Larma, I; Nelson, DJ; Nowak, AK | 1 |
| Bagavant, H; Deshmukh, US; Gmyrek, GB; Papinska, J | 1 |
| Bang, S; Donnelly, CR; Hilton, MJ; Ji, RR; Jiang, C; Lee, M; Liao, Y; Luo, X; McGinnis, A; Tao, X; Wang, K | 1 |
| Bagavant, H; Deshmukh, US; Fitzgerald, KA; Gmyrek, GB; Papinska, J; Sroka, M; Tummala, S | 1 |
| Hu, Q; Huang, J; Li, G; Ren, H; Ren, J; Slade, DA; Wang, D; Wu, J; Wu, X; Zheng, J; Zhou, Q | 1 |
| Dwinell, MB; Gershan, J; Jing, W; Johnson, BD; McAllister, D; Palen, K; Riese, MJ; Vonderhaar, EP | 1 |
| Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R | 1 |
| Bertelsen, LB; Bohn, AB; Falborg, L; Horsman, MR; Shen, YY; Stødkilde-Jørgensen, H | 1 |
| Chen, X; Corrales, L; Curran, E; Dubensky, TW; Duttagupta, P; Kline, DE; Kline, J; Kortylewski, M | 1 |
| Hung, CF; Monie, A; Pang, X; Peng, S; Wu, TC; Yang, M; Zeng, Q | 1 |
| Albelda, SM; Burdick, MD; Cheung, L; Ching, LM; Jassar, AS; Kaiser, LR; Kapoor, V; Silverberg, MB; Strieter, RM; Sun, J; Suzuki, E | 1 |
| Chaplin, DJ; Horsman, MR; Siemann, DW | 1 |
1 review(s) available for vadimezan and Disease Models, Animal
| Article | Year |
|---|---|
Current development status of small-molecule vascular disrupting agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones | 2006 |
12 other study(ies) available for vadimezan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Disease Models, Animal; Mesothelioma; Mesothelioma, Malignant; Mice; Ovalbumin; T-Lymphocytes, Cytotoxic | 2022 |
Pulmonary Involvement in a Mouse Model of Sjögren's Syndrome Induced by STING Activation.
Topics: Animals; Antibodies, Antinuclear; Autoantibodies; Chemokines; Disease Models, Animal; Female; Inflammation; Interferon Type I; Interferon-gamma; Lung; Membrane Proteins; Mice; Mice, Inbred C57BL; Sjogren's Syndrome; Xanthones | 2020 |
STING suppresses bone cancer pain via immune and neuronal modulation.
Topics: Analgesics; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Female; Femur; Ganglia, Spinal; Homeodomain Proteins; Hyperalgesia; Interferons; Male; Mammary Neoplasms, Animal; Membrane Proteins; Mice, Inbred C57BL; Neoplasm Metastasis; Neurons; Nociception; Osteoclasts; Osteogenesis; Receptor, Interferon alpha-beta; Signal Transduction; Tumor Burden; Tumor Microenvironment; Xanthones | 2021 |
Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome.
Topics: Animals; Autoantibodies; Cytokines; Cytosol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Immunity, Innate; Interferon-gamma; Interferons; Membrane Proteins; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Saliva; Signal Transduction; Sjogren's Syndrome; Xanthones | 2018 |
STING-mediated intestinal barrier dysfunction contributes to lethal sepsis.
Topics: Animals; Apoptosis; Bacteria; Cytokines; Dendritic Cells; Disease Models, Animal; DNA, Mitochondrial; Epithelial Cells; Humans; Interferon Regulatory Factor-3; Intestinal Mucosa; Intestines; Leukocytes, Mononuclear; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Sepsis; Xanthones | 2019 |
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Homeodomain Proteins; Humans; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Membrane Proteins; Mice; Mice, Knockout; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Escape; Tumor Microenvironment; Xanthones | 2019 |
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones | 2014 |
Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Carcinoma; Cell Movement; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Female; Fetal Blood; Humans; Indium Radioisotopes; Mice; Mice, Nude; Stilbenes; Xanthones | 2014 |
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Topics: Adaptive Immunity; Animals; Antigen-Presenting Cells; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Genetic Engineering; Humans; Immunity, Innate; Immunologic Memory; Interferon Type I; Leukemia, Myeloid, Acute; Membrane Proteins; Mice, Inbred C57BL; Signal Transduction; Survival Analysis; Xanthones | 2016 |
Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; Disease Models, Animal; Female; Human papillomavirus 16; Mice; Mice, Inbred C57BL; Papillomavirus E7 Proteins; Papillomavirus Vaccines; T-Lymphocytes, Cytotoxic; Tumor Microenvironment; Uterine Cervical Neoplasms; Xanthones | 2011 |
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokines; Cytokines; Disease Models, Animal; Immunotherapy; Lung Neoplasms; Macrophages; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neovascularization, Pathologic; Perforin; Pore Forming Cytotoxic Proteins; Xanthones | 2005 |